Lumida
/LAB
⌘K
Standard BioTools Inc

Standard BioTools Inc

LAB
$0.69USD↑+0.04%+0.00 today

MARKET CAP

270.9M

P/E (TTM)

2.7x

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1
$2

AI Summary

Stalk
Sell NowHigh

In this Stage 4 decline, price has broken key support with a Support Failure pattern, and short-term and long-term trends remain down. Despite extreme oversold conditions, there are no signs of stabilization or institutional demand, with declining EMAs acting as resistance. Execution posture is bearish with the medium-term tradable side permitting a sell into rallies. Given unfavorable timing conditions for entering new bearish positions, execution should occur now on any relief bounce into EMAs or resistance areas.

  • ↑110% upside to $1.35 consensus target from $0.64 current price.
  • ↑Pipeline of innovative bio-tools may expand market share.
  • ↓Negative earnings yield and profitability indicate weak return generation.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Standard BioTools Inc. (NASDAQ: LAB) is an emerging player in the life sciences industry, primarily focusing on tools and technologies for scientific research, diagnostics, and biomedicine. The company is part of the rising trend towards personalized medicine and precision health, providing researchers and laboratories with innovative tools to advance scientific discovery.

Bull says

  • ↑110% upside to $1.35 consensus target from $0.64 current price.
  • ↑Pipeline of innovative bio-tools may expand market share.
  • ↑High QS score signals strong balance sheet stability.
  • ↑Book-to-price ratio suggests undervaluation relative to assets.
  • ↑Positive oil sensitivity could boost demand if energy sector recovers.
  • ↑Personalized medicine trend underpins long-term growth potential.

Bear says

  • ↓Negative earnings yield and profitability indicate weak return generation.
  • ↓Stock down 9.9% over 10 days; -1.7% latest session.
  • ↓Analysts rate ‘Reduce’ and forecast -30% to ~$0.44 in 3 months.
  • ↓High volatility and elevated short interest heighten downside risk.
  • ↓MACD turned negative, confirming bearish momentum.
  • ↓Competition and regulatory headwinds may impair pipeline commercialization.

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 07-31-2026neutral

Transcript signals

Bull points

  • Our solution, together with Illumina, is highly competitive, and the advantage really lies in the SomaScan assay, which I alluded to it before, but the underlying advantage is that our technology is scalable. We see many, many more proteins, and we see them at a much, much lower CV, which means that the discovery power of our assay is manifold larger than that of O-Links. And without discussing cost, but they're sort of in the same ballpark, we think we are highly advantaged in the long term.
  • our pro forma combined revenue was just over $46 million, which grew about 2%, largely in line with expectations.
  • SomaScan-related business contributed about $24 million in revenue for the quarter, grew over 20%, and that's on healthy demand from SomaScan customers.

Bear points

  • down 12% over last year, and that's due primarily to the lingering economic headwinds we mentioned, most notably impacting capital budgets in both biopharma, academic research, as well as continuing pressure outside the US.
  • cash burn was unusually high in the quarter due to several merger-related and other non-operating uses of cash.
  • our consumable and service business, which now includes SomaScan and its high-quality service offering, are helping to smooth our growth while we continue to expand our overall corporate growth margins and reduce cost and cash burn.
Read full transcript analysis ›